This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
intensive care | 795 |
mechanical ventilation | 520 |
acute respiratory | 479 |
critically ill | 406 |
care unit | 397 |
respiratory distress | 355 |
septic shock | 350 |
distress syndrome | 313 |
ill patients | 305 |
respiratory failure | 243 |
ethics regulations | 238 |
icu admission | 231 |
patients admitted | 207 |
risk factors | 187 |
lung injury | 170 |
icu stay | 139 |
mortality rate | 136 |
prone positioning | 131 |
multivariate analysis | 131 |
additional file | 130 |
hospital mortality | 130 |
cardiac arrest | 123 |
two groups | 123 |
pao fio | 119 |
retrospective study | 116 |
sofa score | 115 |
ards patients | 115 |
severe acute | 107 |
care units | 107 |
organ failure | 105 |
severe ards | 105 |
observational study | 105 |
replacement therapy | 103 |
renal replacement | 103 |
icu patients | 100 |
study period | 98 |
mechanically ventilated | 98 |
tidal volume | 96 |
university hospital | 94 |
mean age | 92 |
membrane oxygenation | 92 |
ml kg | 91 |
factors associated | 90 |
extracorporeal membrane | 88 |
day mortality | 88 |
critical care | 86 |
prospective study | 85 |
arterial pressure | 85 |
adult patients | 84 |
airway pressure | 82 |
kidney injury | 80 |
associated pneumonia | 79 |
significantly higher | 79 |
expiratory pressure | 79 |
respiratory syndrome | 78 |
invasive ventilation | 76 |
antibiotic therapy | 76 |
independently associated | 76 |
saps ii | 76 |
patients received | 74 |
driving pressure | 74 |
acute kidney | 73 |
control group | 73 |
patients receiving | 70 |
icu mortality | 70 |
ventilated patients | 69 |
univariate analysis | 68 |
pulmonary vascular | 68 |
positive end | 68 |
invasive mechanical | 68 |
novel coronavirus | 67 |
blood flow | 67 |
included patients | 66 |
acute lung | 65 |
cohort study | 65 |
systematic review | 63 |
median age | 62 |
cardiogenic shock | 61 |
ecmo team | 60 |
mg kg | 60 |
respiratory tract | 60 |
logistic regression | 60 |
among patients | 59 |
acquired pneumonia | 59 |
patients treated | 59 |
prone position | 58 |
randomized controlled | 58 |
clinical outcomes | 58 |
risk factor | 57 |
controlled trial | 57 |
brain injury | 56 |
significant difference | 56 |
international congresses | 54 |
spontaneous breathing | 53 |
patients without | 53 |
patients hospitalized | 53 |
fio ratio | 53 |
respiratory rate | 52 |
high risk | 52 |
years old | 52 |
present study | 51 |
sex ratio | 50 |
hospital stay | 49 |
lung volume | 49 |
respiratory support | 49 |
first days | 49 |
nosocomial infections | 49 |
respiratory mechanics | 49 |
ann intensive | 49 |
extradiaphragmatic inspiratory | 48 |
doc id | 47 |
care doi | 47 |
poor outcome | 47 |
severe sepsis | 47 |
prognostic factors | 47 |
heart rate | 47 |
clinical trial | 47 |
cord uid | 47 |
clinical practice | 46 |
regional strain | 46 |
renal failure | 46 |
significantly associated | 46 |
blood pressure | 46 |
pulmonary edema | 45 |
pulmonary disease | 45 |
copd patients | 45 |
noninvasive ventilation | 45 |
cardiac output | 45 |
coronavirus disease | 44 |
central venous | 44 |
east respiratory | 44 |
middle east | 44 |
interquartile range | 44 |
one patient | 43 |
fluid balance | 43 |
respiratory system | 43 |
chronic obstructive | 43 |
medical icu | 43 |
performed using | 42 |
high mortality | 42 |
shock patients | 42 |
obstructive pulmonary | 42 |
flow nasal | 41 |
oxygen therapy | 41 |
least one | 41 |
statistical analysis | 41 |
plateau pressure | 41 |
syndrome coronavirus | 41 |
severe covid | 41 |
organ dysfunction | 41 |
body weight | 41 |
critical illness | 40 |
mortality rates | 40 |
right ventricular | 40 |
vascular resistance | 40 |
pressure support | 40 |
primary outcome | 39 |
fluid administration | 39 |
health care | 39 |
informed consent | 39 |
pediatric intensive | 39 |
arterial blood | 39 |
patients included | 39 |
lung recruitment | 38 |
infected patients | 38 |
family members | 38 |
consecutive patients | 38 |
confidence interval | 38 |
predictive factors | 38 |
pulmonary arterial | 38 |
higher mortality | 37 |
nature remains | 37 |
patients requiring | 37 |
institutional affiliations | 37 |
remains neutral | 37 |
icu discharge | 37 |
two patients | 37 |
springer nature | 37 |
jurisdictional claims | 37 |
muscle activity | 37 |
significant increase | 37 |
cmv reactivation | 37 |
fluid responsiveness | 37 |
lung water | 37 |
emergency department | 37 |
study conducted | 37 |
published maps | 37 |
clinical characteristics | 37 |
icu length | 36 |
hospitalized patients | 36 |
year period | 36 |
increased mortality | 36 |
authors read | 36 |
protective ventilation | 35 |
final manuscript | 35 |
statistically significant | 35 |
nasal cannula | 35 |
adverse events | 35 |
convalescent plasma | 35 |
ii score | 34 |
care medicine | 34 |
nitric oxide | 34 |
traumatic brain | 34 |
lower respiratory | 34 |
significantly lower | 34 |
prospective observational | 34 |
independent risk | 34 |
failure assessment | 34 |
respiratory virus | 33 |
fluid resuscitation | 33 |
public health | 33 |
immunocompromised patients | 33 |
acute physiology | 33 |
tracheal intubation | 33 |
longer duration | 33 |
vps dsi | 33 |
clinical trials | 32 |
fluid therapy | 32 |
icu beds | 32 |
apache ii | 32 |
inspiratory muscles | 32 |
mean arterial | 32 |
life support | 32 |
clinical features | 32 |
current study | 32 |
note springer | 32 |
bal fluid | 32 |
pilot study | 32 |
respiratory viruses | 32 |
gas exchange | 32 |
carbon dioxide | 31 |
increased risk | 31 |
support scientific | 31 |
cardiac surgery | 31 |
predictive value | 31 |
odds ratio | 31 |
berlin definition | 31 |
scientific studies | 31 |
research support | 31 |
hypoxemic respiratory | 30 |
niv failure | 30 |
previous studies | 30 |
kidney disease | 30 |
exclusion criteria | 30 |
randomized clinical | 30 |
intubated patients | 30 |
leading cause | 30 |
pseudomonas aeruginosa | 30 |
elderly patients | 29 |
septic patients | 29 |
neurological outcome | 29 |
study including | 29 |
i ratio | 29 |
average age | 29 |
team group | 29 |
one hundred | 29 |
simplified acute | 29 |
pulmonary embolism | 29 |
tidal volumes | 29 |
significantly different | 29 |
heart failure | 29 |
long term | 29 |
diaphragm dysfunction | 29 |
study aimed | 28 |
partial pressure | 28 |
acute hypoxemic | 28 |
sequential organ | 28 |
ventilator settings | 28 |
serum creatinine | 28 |
ng ml | 28 |
antibiotic treatment | 28 |
cardiac index | 28 |
poor prognosis | 28 |
retrospective analysis | 28 |
pulmonary hypertension | 28 |
significant differences | 28 |
medical intensive | 27 |
multiple organ | 27 |
dead space | 27 |
inflammatory response | 27 |
peep cmh | 27 |
ventilatory support | 27 |
influenza pneumonia | 27 |
poorly recruitable | 27 |
pk pd | 27 |
endotracheal tube | 27 |
authors declare | 27 |
blood gas | 27 |
prospective cohort | 27 |
four patients | 27 |
induced lung | 27 |
release phase | 27 |
retrospective cohort | 27 |
staphylococcus aureus | 27 |
hospital length | 26 |
extubation failure | 26 |
center study | 26 |
compared using | 26 |
body mass | 26 |
severe pjp | 26 |
noninfluenza group | 26 |
data collection | 26 |
nosocomial infection | 26 |
median duration | 25 |
space fraction | 25 |
regression model | 25 |
pneumocystis jirovecii | 25 |
three patients | 25 |
ethics committee | 25 |
acute exacerbation | 25 |
acute renal | 25 |
extravascular lung | 25 |
mers patients | 25 |
patients undergoing | 25 |
cirrhotic patients | 25 |
study included | 25 |
higher risk | 25 |
within days | 25 |
mass index | 25 |
esophageal pressure | 25 |
fluid management | 24 |
shock index | 24 |
mcg ml | 24 |
lymphocyte count | 24 |
bronchoalveolar lavage | 24 |
burn patients | 24 |
cancer patients | 24 |
circulatory failure | 24 |
primary endpoint | 24 |
bacterial infection | 24 |
clinical presentation | 24 |
human metapneumovirus | 24 |
pulmonary artery | 24 |
france correspondence | 24 |
reactive protein | 24 |
competing interests | 24 |
co removal | 24 |
collected data | 23 |
patients presenting | 23 |
monocentric study | 23 |
respiratory drive | 23 |
mean duration | 23 |
arterial ph | 23 |
myocardial infarction | 23 |
nasogastric tube | 23 |
enteral nutrition | 23 |
computed tomography | 23 |
polymerase chain | 23 |
rescue therapy | 23 |
randomized trial | 23 |
liver transplantation | 23 |
left ventricular | 23 |
chronic respiratory | 23 |
ct scan | 23 |
hoc analysis | 23 |
pressure release | 23 |
severe respiratory | 23 |
supine position | 23 |
healthcare workers | 23 |
release ventilation | 23 |
continuous variables | 23 |
severe influenza | 23 |
physiology score | 23 |
chain reaction | 23 |
blood gases | 23 |
required mechanical | 22 |
severe hypoxemia | 22 |
five patients | 22 |
lactate levels | 22 |
prognostic value | 22 |
regression analysis | 22 |
recruitable patients | 22 |
healthy subjects | 22 |
patients required | 22 |
chest wall | 22 |
ngt insertion | 22 |
infection prevention | 22 |
month period | 22 |
severity scores | 22 |
post hoc | 22 |
clinical signs | 22 |
six patients | 22 |
side effects | 22 |
intracranial hypertension | 22 |
including patients | 22 |
preliminary cohort | 22 |
success rate | 22 |
status epilepticus | 22 |
infectious complications | 22 |
inclusion criteria | 22 |
endotracheal intubation | 21 |
pulmonary dead | 21 |
standard care | 21 |
per year | 21 |
low tidal | 21 |
chronic kidney | 21 |
hemodynamic instability | 21 |
pandemic influenza | 21 |
associated infection | 21 |
expiratory flow | 21 |
general anesthesia | 21 |
highly recruitable | 21 |
requiring mechanical | 21 |
european society | 21 |
sample size | 21 |
first attempt | 21 |
dynamic driving | 21 |
median time | 21 |
descriptive study | 21 |
support ventilation | 21 |
inspiratory muscle | 21 |
age years | 21 |
glasgow coma | 20 |
trauma patients | 20 |
exact test | 20 |
ill children | 20 |
adult respiratory | 20 |
study showed | 20 |
ischemic stroke | 20 |
multidisciplinary team | 20 |
aki stage | 20 |
severe infections | 20 |
fluid overload | 20 |
antimicrobial therapy | 20 |
mm hg | 20 |
severity score | 20 |
assessed using | 20 |
patients aged | 20 |
tract infections | 20 |
data suggest | 20 |
clinical data | 20 |
inhaled nitric | 20 |
jirovecii pneumonia | 20 |
saudi arabia | 19 |
results suggest | 19 |
positive airway | 19 |
ml min | 19 |
data analysis | 19 |
high morbidity | 19 |
transpulmonary thermodilution | 19 |
lung disease | 19 |
infectious diseases | 19 |
predicted body | 19 |
prospectively collected | 19 |
per day | 19 |
pulmonary infection | 19 |
deep sedation | 19 |
blood cultures | 19 |
weak recommendation | 19 |
free days | 19 |
inspired oxygen | 19 |
pulmonary syndrome | 19 |
blood culture | 19 |
hemodynamic parameters | 19 |
therapeutic management | 19 |
patients presented | 19 |
may lead | 19 |
may result | 19 |
tcav method | 19 |
medical records | 19 |
expert opinion | 19 |
extracorporeal life | 19 |
eight patients | 18 |
analyzed using | 18 |
extracorporeal co | 18 |
single center | 18 |
respiratory effort | 18 |
peep level | 18 |
supplementary information | 18 |
medical history | 18 |
microcirculatory blood | 18 |
patients died | 18 |
corresponding author | 18 |
overall mortality | 18 |
study performed | 18 |
frequency oscillatory | 18 |
significantly increased | 18 |
significant decrease | 18 |
defined according | 18 |
system compliance | 18 |
patients infected | 18 |
early intubation | 18 |
direct examination | 18 |
respiratory infection | 18 |
viral infection | 18 |
acinetobacter baumannii | 18 |
hospital cardiac | 18 |
information accompanies | 18 |
support outside | 18 |
high flow | 18 |
minute ventilation | 18 |
validation cohort | 18 |
oscillatory ventilation | 18 |
health problem | 18 |
kg min | 18 |
flow oxygen | 18 |
even though | 17 |
continuous renal | 17 |
seven patients | 17 |
roc curve | 17 |
average length | 17 |
alveolar recruitment | 17 |
associated ards | 17 |
negative patients | 17 |
optimal mpaw | 17 |
coronavirus pneumonia | 17 |
study population | 17 |
median length | 17 |
dynamic hyperinflation | 17 |
weaning process | 17 |
institutional review | 17 |
reasonable request | 17 |
impedance tomography | 17 |
care workers | 17 |
multidisciplinary approach | 17 |
identify factors | 17 |
organ support | 17 |
unfavorable outcome | 17 |
infection control | 17 |
tube insertion | 17 |
patient characteristics | 17 |
airway closure | 17 |
vasoactive drugs | 17 |
hazard ratio | 17 |
sofa scores | 17 |
creatinine clearance | 17 |
patients developed | 17 |
electrical activity | 17 |
virus infection | 17 |
teaching hospital | 17 |
right ventricle | 17 |
icu los | 17 |
infectious disease | 17 |
parenteral nutrition | 17 |
discharged alive | 17 |
liver failure | 17 |
data regarding | 16 |
retrospective observational | 16 |
multicenter study | 16 |
cd lymphocyte | 16 |
acute circulatory | 16 |
baseline characteristics | 16 |
lactate level | 16 |
review board | 16 |
onset vap | 16 |
negative bacilli | 16 |
hospital discharge | 16 |
alae nasi | 16 |
stem cell | 16 |
vascular dysfunction | 16 |
klebsiella pneumoniae | 16 |
results patients | 16 |
clinical course | 16 |
prospective multicenter | 16 |
ecmo patients | 16 |
data acquisition | 16 |
international guidelines | 16 |
incidence rate | 16 |
considered significant | 16 |
nine patients | 16 |
hepatic encephalopathy | 16 |
lung tissue | 16 |
sort maneuver | 16 |
aspiration pneumonia | 16 |
early stage | 16 |
patients underwent | 16 |
shockable rhythm | 16 |
volume expansion | 16 |
oxygen saturation | 16 |
derivation cohort | 16 |
control study | 16 |
ecmo group | 16 |
weaning failure | 16 |
practice guidelines | 16 |
ventilation distribution | 15 |
main objective | 15 |
hfnc failure | 15 |
hsv cmv | 15 |
previously described | 15 |
vasopressor support | 15 |
cranial trauma | 15 |
sepsis campaign | 15 |
group versus | 15 |
cov infection | 15 |
medical staff | 15 |
burned patients | 15 |
respiratory muscles | 15 |
median sofa | 15 |
standard deviation | 15 |
cor pulmonale | 15 |
hand hygiene | 15 |
cox model | 15 |
groups according | 15 |
pleural effusion | 15 |
patients intubated | 15 |
medical care | 15 |
missing data | 15 |
clinical outcome | 15 |
surviving sepsis | 15 |
icu alos | 15 |
peep levels | 15 |
blood samples | 15 |
last years | 15 |
intellectual content | 15 |
electrical impedance | 15 |
acute pancreatitis | 15 |
per patient | 15 |
hypercapnic respiratory | 15 |
rank test | 15 |
ten patients | 15 |
primary objective | 15 |
respiratory acidosis | 14 |
observational cohort | 14 |
high rate | 14 |
chest tube | 14 |
neuromuscular blockers | 14 |
significant association | 14 |
may help | 14 |
epidemiological characteristics | 14 |
organ donation | 14 |
ventilation strategy | 14 |
icu team | 14 |
lung recruitability | 14 |
open access | 14 |
adverse effects | 14 |
prognostic impact | 14 |
diastolic shock | 14 |
demographic data | 14 |
healthcare use | 14 |
unfractionated heparin | 14 |
commonly used | 14 |
inspiratory effort | 14 |
influenza infection | 14 |
lung regions | 14 |
receiver operating | 14 |
failure requiring | 14 |
ml cmh | 14 |
venous catheter | 14 |
recruited lung | 14 |
recent studies | 14 |
independent predictors | 14 |
whole population | 14 |
analysis showed | 14 |
influenza patients | 14 |
acquired weakness | 14 |
flow rate | 14 |
respiratory samples | 14 |
metabolic acidosis | 14 |
relative risk | 14 |
continuous positive | 14 |
inspiratory time | 14 |
interstitial lung | 14 |
acinetobacter baumanii | 14 |
spontaneously breathing | 14 |
alveolar damage | 14 |
early phase | 14 |
ill adults | 14 |
study shows | 14 |
negative predictive | 14 |
ecmo support | 14 |
time spent | 14 |
secondary outcomes | 14 |
biological data | 14 |
important intellectual | 14 |
united states | 14 |
herpesviridae reactivation | 14 |
tissue perfusion | 14 |
categorical variables | 14 |
beneficial effect | 13 |
lung ultrasound | 13 |
transthoracic echocardiography | 13 |
experts suggest | 13 |
volume ventilation | 13 |
randomized trials | 13 |
systolic blood | 13 |
immune system | 13 |
del lili | 13 |
secondary objectives | 13 |
enteral feeding | 13 |
systolic function | 13 |
ventricular failure | 13 |
lung strain | 13 |
antibiotic prophylaxis | 13 |
preliminary results | 13 |
antibiotic prescription | 13 |
slope fe | 13 |
surgical intensive | 13 |
glasgow score | 13 |
datasets used | 13 |
care med | 13 |
hematological malignancies | 13 |
study design | 13 |
diabetic ketoacidosis | 13 |
intravenous fluid | 13 |
weaning protocol | 13 |
fluid loading | 13 |
controlled trials | 13 |
health workers | 13 |
hiv infection | 13 |
factors independently | 13 |
platelet count | 13 |
survival rate | 13 |
identify patients | 13 |
may also | 13 |
year survival | 13 |
receiving respiratory | 13 |
invasive aspergillosis | 13 |
previously reported | 13 |
emg peak | 13 |
atrial fibrillation | 13 |
regional lung | 13 |
hematologic malignancies | 13 |
assess whether | 13 |
world health | 13 |
clinical pulmonary | 13 |
written informed | 13 |
study protocol | 13 |
cpis value | 13 |
first day | 13 |
cpap phase | 13 |
lung protective | 13 |
coronavirus infection | 13 |
arterial oxygen | 13 |
mers cases | 13 |
urinary tract | 13 |
refractory cardiac | 13 |
gold standard | 13 |
pulmonary oedema | 13 |
severe patients | 13 |
invasive fungal | 13 |
acute poisoning | 13 |
valle del | 13 |
multivariate logistic | 13 |
studies reported | 13 |
hypoxic pulmonary | 13 |
acute brain | 13 |
patients experienced | 13 |
respiratory infections | 12 |
french icus | 12 |
recruitment maneuver | 12 |
urinary output | 12 |
refractory cardiogenic | 12 |
significantly reduced | 12 |
diffuse alveolar | 12 |
statistical analyses | 12 |
induced changes | 12 |
common cause | 12 |
pulmonary manifestations | 12 |
resistant bacteria | 12 |
least days | 12 |
determined using | 12 |
abdominal surgery | 12 |
positive predictive | 12 |
clinical manifestations | 12 |
icu teams | 12 |
loading dose | 12 |
end expiratory | 12 |
sodium lactate | 12 |
hsv reactivation | 12 |
care department | 12 |
arterial lactate | 12 |
blood cell | 12 |
linear mixed | 12 |
following criteria | 12 |
antibiotic susceptibility | 12 |
injury severity | 12 |
surface emg | 12 |
blood volume | 12 |
pulmonary vasoconstriction | 12 |
mesenteric ischemia | 12 |
rr adjustment | 12 |
multidisciplinary ecmo | 12 |
making process | 12 |
bacterial pneumonia | 12 |
inhibitory concentration | 12 |
susceptibility testing | 12 |
stroke volume | 12 |
bed icu | 12 |
renal function | 12 |
lopinavir ritonavir | 12 |
independent predictor | 12 |
patients suffering | 12 |
pneumocystis carinii | 12 |
urine output | 12 |
operating room | 12 |
positive fluid | 12 |
average time | 12 |
bed medical | 12 |
moderate ards | 12 |
quantitative variables | 12 |
requiring icu | 12 |
solid tumors | 12 |
fluid challenge | 12 |
lower tidal | 12 |
high peep | 12 |
transplant recipients | 12 |
scatter plot | 12 |
worse outcomes | 12 |
herpes simplex | 12 |
health organization | 12 |
failure rate | 12 |
ill covid | 12 |
prospective studies | 12 |
blood products | 12 |
brain death | 12 |
working group | 12 |
ali ards | 12 |
intubated early | 12 |
hypoxemic patients | 12 |
myocardial dysfunction | 12 |
peak airway | 12 |
prognostic factor | 12 |
prolonged mechanical | 12 |
days following | 12 |
influenza virus | 12 |
lower mortality | 12 |
steady state | 12 |
higher rate | 12 |
sort group | 12 |
breathing trial | 12 |
related ards | 12 |
surgical patients | 12 |
vascular tone | 12 |
mechanical ventilator | 12 |
blood transfusion | 12 |
infection score | 12 |
nasal oxygen | 12 |
space ventilation | 12 |
patients still | 12 |
previous study | 12 |
associated events | 12 |
nervous system | 12 |
pg ml | 12 |
plot depicting | 12 |
secondary infection | 11 |
ibn rochd | 11 |
thymosin alpha | 11 |
diastolic dysfunction | 11 |
cardiopulmonary resuscitation | 11 |
simplex virus | 11 |
acute cor | 11 |
disease severity | 11 |
multivariate regression | 11 |
poor outcomes | 11 |
task force | 11 |
clinical studies | 11 |
coma scale | 11 |
icu staff | 11 |
study suggests | 11 |
see additional | 11 |
male gender | 11 |
prone ventilation | 11 |
ncip patients | 11 |
multicenter cohort | 11 |
median delay | 11 |
immunodeficiency virus | 11 |
early sepsis | 11 |
surgical site | 11 |
carbon monoxide | 11 |
lst limitation | 11 |
chronic health | 11 |
mait cells | 11 |
survival analysis | 11 |
financial support | 11 |
infected pneumonia | 11 |
balanced solutions | 11 |
therapeutic hypothermia | 11 |
heart disease | 11 |
children aged | 11 |
neutropenic patients | 11 |
diagnostic criteria | 11 |
severe pneumonia | 11 |
higher peep | 11 |
poor neurological | 11 |
pulmonary aspergillosis | 11 |
independent factors | 11 |
significant correlation | 11 |
solid organ | 11 |
large number | 11 |
french intensive | 11 |
endothelial cells | 11 |
statistical significance | 11 |
protective effect | 11 |
hospital admission | 11 |
nosocomial pneumonia | 11 |
diastolic arterial | 11 |
artery catheter | 11 |
bacterial resistance | 11 |
carinii pneumonia | 11 |
observational studies | 11 |
pd target | 11 |
refractory hypoxemia | 11 |
pulmonary blood | 11 |
respiratory variations | 11 |
volumetric strain | 11 |
clinically relevant | 11 |
high level | 11 |
successful insertion | 11 |
lung collapse | 11 |
first pass | 11 |
early diagnosis | 11 |
center effect | 11 |
much higher | 11 |
fresenius medical | 11 |
tract infection | 11 |
children admitted | 11 |
continuous infusion | 11 |
ventilator associated | 11 |
first study | 11 |
immune response | 11 |
acquired infections | 11 |
associated tracheobronchitis | 11 |
acute phase | 11 |
patients discharged | 11 |
bacterial coinfection | 11 |
clinical examination | 11 |
viral pneumonia | 11 |
lumbar puncture | 11 |
secondary objective | 11 |
suspected infection | 11 |
acute pulmonary | 11 |
transpulmonary pressure | 11 |
isolated bacteria | 11 |
human immunodeficiency | 11 |
critical revision | 11 |
evaluated using | 11 |
local signs | 11 |
linear regression | 11 |
opportunistic infections | 11 |
fungal infection | 11 |
positive patients | 11 |
systemic inflammatory | 11 |
underlying disease | 11 |
receiving prone | 11 |
main causes | 11 |
endotracheal aspirate | 10 |
main reason | 10 |
oxygen fraction | 10 |
demographic characteristics | 10 |
early acute | 10 |
flow curve | 10 |
standard oxygen | 10 |
limited number | 10 |
delta pco | 10 |
intubation rate | 10 |
ventricular dysfunction | 10 |
patients within | 10 |
prospective randomized | 10 |
study group | 10 |
vital signs | 10 |
pulmonary fibrosis | 10 |
major adverse | 10 |
widely used | 10 |
end point | 10 |
primary end | 10 |
lung cancer | 10 |
high levels | 10 |
hemoglobin level | 10 |
severe traumatic | 10 |
resuscitation department | 10 |
resuscitation fluids | 10 |
disk diffusion | 10 |
icu bed | 10 |
cell count | 10 |
fr annals | 10 |
early use | 10 |
health evaluation | 10 |
patient outcomes | 10 |
high dose | 10 |
personal fees | 10 |
patients diagnosed | 10 |
acute mesenteric | 10 |
dosing regimens | 10 |
decompressive craniectomy | 10 |
year mortality | 10 |
antiviral therapy | 10 |
several studies | 10 |
per ventilator | 10 |
flow distribution | 10 |
mv duration | 10 |
circulatory shock | 10 |
respiratory parameters | 10 |
thirty patients | 10 |
lavage fluid | 10 |
igs ii | 10 |
viral co | 10 |
endothelial dysfunction | 10 |
ventilation strategies | 10 |
dsi values | 10 |
venous extracorporeal | 10 |
venous blood | 10 |
access correspondence | 10 |
case series | 10 |
prospectively included | 10 |
average duration | 10 |
every patient | 10 |
fio decreases | 10 |
neuromuscular blocking | 10 |
group compared | 10 |
also collected | 10 |
diffusion method | 10 |
beneficial effects | 10 |
respiratory depression | 10 |
investigate whether | 10 |
eligible patients | 10 |
admitted patients | 10 |
converting enzyme | 10 |
positive culture | 10 |
mean saps | 10 |
atrial pressure | 10 |
iv infection | 10 |
phase i | 10 |
good outcome | 10 |
hd tgc | 10 |
lung aeration | 10 |
final version | 10 |
pediatric ards | 10 |
hiv patients | 10 |
bloodstream infections | 10 |
pneumonia severity | 10 |
ami patients | 10 |
rel rs | 10 |
data collected | 10 |
chest trauma | 10 |
severe brain | 10 |
first weeks | 10 |
niv hfnc | 10 |
gas exchanges | 10 |
body temperature | 10 |
dysfunction failure | 10 |
sublingual microcirculation | 10 |
coronary artery | 10 |
considered statistically | 10 |
general population | 10 |
venous pressure | 10 |
prior antibiotic | 10 |
clinical study | 10 |
cardiac function | 10 |
head trauma | 10 |
cytokine storm | 10 |
clinical impact | 10 |
ps level | 10 |
cox regression | 10 |
per minute | 10 |
mental health | 10 |
acute myocardial | 10 |
expiratory time | 10 |
open lung | 10 |
ab vap | 10 |
following icu | 10 |
several limitations | 10 |
increased significantly | 10 |
oxygen consumption | 10 |
mortality among | 10 |
expiratory duration | 10 |
com annals | 10 |
group without | 10 |
early identification | 10 |
kdigo criteria | 10 |
eadi peak | 10 |
mortality risk | 9 |
sweep gas | 9 |
organ failures | 9 |
mg dl | 9 |
low flow | 9 |
head injury | 9 |
normally distributed | 9 |
drug monitoring | 9 |
transition period | 9 |
plateau pressures | 9 |
approval number | 9 |
study confirms | 9 |
dosage regimen | 9 |
twelve patients | 9 |
abdominal infections | 9 |
plasma therapy | 9 |
validation cohorts | 9 |
systolic dysfunction | 9 |
large prospective | 9 |
fisher exact | 9 |
rescue therapies | 9 |
antimicrobial susceptibility | 9 |
two methods | 9 |
qsofa score | 9 |
first episode | 9 |
hemorrhagic shock | 9 |
antiretroviral therapy | 9 |
another hospital | 9 |
high doses | 9 |
endexpiratory pressure | 9 |
cardiac dysfunction | 9 |
alveolar lavage | 9 |
ivc diameter | 9 |
major cause | 9 |
similar results | 9 |
frequent complication | 9 |
also associated | 9 |
prolonged icu | 9 |
male predominance | 9 |
low peep | 9 |
better survival | 9 |
performance status | 9 |
identify risk | 9 |
favorable outcome | 9 |
fungal infections | 9 |
preventive measures | 9 |
pneumocystis pneumonia | 9 |
positive endexpiratory | 9 |
pulmonary syndromes | 9 |
clinical cure | 9 |
determine whether | 9 |
fluid creep | 9 |
one third | 9 |
predict fluid | 9 |
clinical parameters | 9 |
receiving invasive | 9 |
delta nlr | 9 |
term outcomes | 9 |
retrospective nature | 9 |
severe bronchiolitis | 9 |
purulent discharge | 9 |
chest radiograph | 9 |
personal protective | 9 |
rheumatoid arthritis | 9 |
plasma exchange | 9 |
patient died | 9 |
main reasons | 9 |
mechanical power | 9 |
blood glucose | 9 |
extracorporeal blood | 9 |
chest radiography | 9 |
one patients | 9 |
induced pulmonary | 9 |
muscle weakness | 9 |
protocol group | 9 |
renal impairment | 9 |
qualitative variables | 9 |
acute exacerbations | 9 |
overall survival | 9 |
term survival | 9 |
lung units | 9 |
without significant | 9 |
icu survivors | 9 |
strong association | 9 |
median saps | 9 |
care patients | 9 |
patients compared | 9 |
respiratory muscle | 9 |
related organ | 9 |
enrolled patients | 9 |
patients ventilated | 9 |
pulmonary infections | 9 |
large cohort | 9 |
may contribute | 9 |
term mortality | 9 |
directed therapy | 9 |
coma score | 9 |
functional residual | 9 |
inflammatory myopathies | 9 |
residual capacity | 9 |
continuous veno | 9 |
protective equipment | 9 |
controlled mode | 9 |
receiving mechanical | 9 |
statistically different | 9 |
chest physiotherapy | 9 |
hospital charges | 9 |
normal lung | 9 |
charlson comorbidity | 9 |
general hospital | 9 |
square test | 9 |
multicenter prospective | 9 |
operating characteristic | 9 |
good neurological | 9 |
vascular cause | 9 |
fluid bolus | 9 |
underlying malignancy | 9 |
difficult intubation | 9 |
regional deformation | 9 |
antisynthetase syndrome | 9 |
lung damage | 9 |
severe tbi | 9 |
care resources | 9 |
severe infection | 9 |
regional ventilation | 9 |
heart association | 9 |
secondary infections | 9 |
global strain | 9 |
flow cytometry | 9 |
severe mers | 9 |
therapeutic drug | 9 |
pulmonary haemodynamics | 9 |
clinical research | 9 |
severe cases | 9 |
ventilatory settings | 9 |
remains high | 9 |
following data | 9 |
treatment failure | 9 |
healthy volunteers | 9 |
related infections | 9 |
respiratory viral | 9 |
viral infections | 9 |
multivariable logistic | 9 |
oral care | 9 |
specialized advice | 9 |
left ventricle | 9 |
viral documentation | 9 |
monocentric retrospective | 9 |
systemic inflammation | 9 |
brain damage | 9 |
igs score | 9 |
among critically | 9 |
immune responses | 9 |
resistant strains | 9 |
pulmonary circulation | 9 |
breathing patients | 9 |
mixed icu | 9 |
common risk | 8 |
patients will | 8 |
icu respiratory | 8 |
obese patients | 8 |
passive leg | 8 |
first admission | 8 |
developed vap | 8 |
associated aki | 8 |
early start | 8 |
icu management | 8 |
patient management | 8 |
leg raising | 8 |
significantly longer | 8 |
survival rates | 8 |
ionized calcium | 8 |
initial severity | 8 |
acute coronary | 8 |
tertiary care | 8 |
study day | 8 |
ulcerative colitis | 8 |
hemodynamic monitoring | 8 |
hemodynamic profile | 8 |
predict mortality | 8 |
patient without | 8 |
significantly related | 8 |
central nervous | 8 |
significantly decreased | 8 |
closely related | 8 |
main outcome | 8 |
normal saline | 8 |
clinical evidence | 8 |
selected patients | 8 |
retrospectively studied | 8 |
lung infection | 8 |
recent study | 8 |
first week | 8 |
copd exacerbation | 8 |
severe aki | 8 |
median value | 8 |
healthcare system | 8 |
chronic liver | 8 |
pressure rooms | 8 |
factors related | 8 |
inspiratory flow | 8 |
improving global | 8 |
site infection | 8 |
groups regarding | 8 |
shock population | 8 |
regional volumetric | 8 |
study reported | 8 |
dioxide removal | 8 |
hematological malignancy | 8 |
severe community | 8 |
month mortality | 8 |
confounding factors | 8 |
corticosteroid therapy | 8 |
bone marrow | 8 |
eeg reactivity | 8 |
nutritional support | 8 |
time points | 8 |
early vap | 8 |
time course | 8 |
hospital center | 8 |
small sample | 8 |
patients older | 8 |
prehospital setting | 8 |
right heart | 8 |
chronic heart | 8 |
oxygen concentrator | 8 |
opening pressure | 8 |
ventilator support | 8 |
author information | 8 |
ecmo program | 8 |
emergency room | 8 |
host response | 8 |
chu angers | 8 |
blocking agents | 8 |
citrate anticoagulation | 8 |
glucocorticoid therapy | 8 |
significantly improved | 8 |
hypercapnic acidosis | 8 |
full list | 8 |
ventilation may | 8 |
hemorrhagic stroke | 8 |
global outcomes | 8 |
invasive respiratory | 8 |
fluid volume | 8 |
well known | 8 |
volumetric capnography | 8 |
deeply sedated | 8 |
twenty patients | 8 |
generating procedures | 8 |
fisher paykel | 8 |
differentiate vat | 8 |
score ii | 8 |
tunisia correspondence | 8 |
adverse drug | 8 |
microbiological documentation | 8 |
burn intensive | 8 |
cardiogenic pulmonary | 8 |
cell transplantation | 8 |
ultraprotective ventilation | 8 |
therapeutic strategies | 8 |
simplified score | 8 |
high respiratory | 8 |
improve survival | 8 |
drug administration | 8 |
fio mmhg | 8 |
bacterial meningitis | 8 |
intervention group | 8 |
dose tigecycline | 8 |
feeding tube | 8 |
antiviral drugs | 8 |
lactate clearance | 8 |
inspiratory pressure | 8 |
randomised controlled | 8 |
risk patients | 8 |
mpaw step | 8 |
spearman rho | 8 |
continuous intravenous | 8 |
required invasive | 8 |
retrospective monocentric | 8 |
diaphragm activity | 8 |
chi square | 8 |
older age | 8 |
antimicrobial resistance | 8 |
diagnostic accuracy | 8 |
improved survival | 8 |
confirmed cases | 8 |
venous ecmo | 8 |
small number | 8 |
assessment score | 8 |
high prevalence | 8 |
results one | 8 |
antiviral treatment | 8 |
lung mechanics | 8 |
days vs | 8 |
postoperative infections | 8 |
kg pbw | 8 |
mpaw titration | 8 |
previously published | 8 |
peak pressure | 8 |
respiratory disease | 8 |
respiratory syncytial | 8 |
remains controversial | 8 |
measured using | 8 |
case report | 8 |
association study | 8 |
patients showed | 8 |
neuromuscular blockade | 8 |
ventilation duration | 8 |
patients whose | 8 |
parasternal intercostals | 8 |
line therapy | 8 |
ill adult | 8 |
high incidence | 8 |
may explain | 8 |
functional status | 8 |
cytomegalovirus reactivation | 8 |
health insurance | 8 |
expiratory muscle | 8 |
french law | 8 |
secondary endpoints | 8 |
roc curves | 8 |
acute stroke | 8 |
regression models | 8 |
significant changes | 8 |
baseline serum | 8 |
systolic arterial | 8 |
injured lung | 8 |
ill patient | 8 |
intravenous fluids | 8 |
multicenter observational | 8 |
mixed model | 8 |
antiviral activity | 8 |
identify variables | 8 |
ventilation time | 8 |
pass success | 8 |
oxygenation parameters | 8 |
rv failure | 8 |
surgical icu | 8 |
bacterial infections | 8 |
clinical efficacy | 8 |
incidence density | 8 |
arrest related | 8 |
rel gene | 8 |
pjp diagnosis | 8 |
missing baseline | 8 |
whitney test | 8 |
organ transplantation | 8 |
berlin criteria | 8 |
retrospective descriptive | 8 |
vap diagnosis | 8 |
intermediate care | 8 |
red blood | 8 |
american heart | 8 |
stroke patients | 8 |
antibiotic use | 8 |
propensity score | 8 |
future studies | 8 |
injured lungs | 8 |
community acquired | 8 |
supportive care | 8 |
therapeutic failure | 8 |
inclusion period | 8 |
target non | 8 |
control practices | 8 |
patients may | 8 |
intracranial pressure | 8 |
clinical decision | 8 |
coronary intervention | 8 |
one case | 8 |
viral load | 8 |
weaning criteria | 8 |
related problems | 8 |
using logistic | 8 |
volume curve | 8 |
minimum inhibitory | 8 |
severe sars | 8 |
study aims | 8 |
rv dysfunction | 8 |
important role | 8 |
reduce mortality | 8 |
recently reported | 8 |
microvascular blood | 8 |
controlled study | 8 |
center retrospective | 8 |
ill cancer | 8 |
medical conditions | 8 |
total peep | 8 |
final diagnosis | 8 |
individual patient | 8 |
death occurred | 8 |
liver cirrhosis | 8 |
type i | 8 |
invasive support | 7 |
ventilation perfusion | 7 |
streptococcus pneumoniae | 7 |
ckd lps | 7 |
testosterone levels | 7 |
prognosis factors | 7 |
vena cava | 7 |
every min | 7 |
decreasing peep | 7 |
variables associated | 7 |
mic values | 7 |
early recognition | 7 |
conventional ventilation | 7 |
final model | 7 |
surface area | 7 |
decreased mortality | 7 |
ards model | 7 |
hemodynamic effects | 7 |
advance directives | 7 |
chest ct | 7 |
vessels perfused | 7 |
organ dysfunctions | 7 |
high rates | 7 |
diaphragmatic paralysis | 7 |
persistent aki | 7 |
ill cirrhotic | 7 |
musical intervention | 7 |
compartment syndrome | 7 |
available data | 7 |
patients group | 7 |
wilcoxon rank | 7 |
spss software | 7 |
ards criteria | 7 |
might allow | 7 |
protective mechanical | 7 |
prognostic significance | 7 |
virus disease | 7 |
drug intoxication | 7 |
patients due | 7 |
main comorbidities | 7 |
confidence intervals | 7 |
oxygen flow | 7 |
care system | 7 |
pulse pressure | 7 |
therapy alone | 7 |
oxygen delivery | 7 |
thyrotropic insufficiency | 7 |
pressure mmhg | 7 |
macintosh laryngoscope | 7 |
venoarterial extracorporeal | 7 |
late vap | 7 |
respiratory insufficiency | 7 |
induced acute | 7 |
serum albumin | 7 |
ohca patients | 7 |
aged years | 7 |
requiring hospitalization | 7 |
systolic shock | 7 |
resuscitation room | 7 |
ards mortality | 7 |
selection bias | 7 |
identified patients | 7 |
ventilator weaning | 7 |
ventilator acquired | 7 |
identified using | 7 |
national health | 7 |
introduction acute | 7 |
remaining patients | 7 |
acute ph | 7 |
internal medicine | 7 |
sublingual mucosa | 7 |
average hospital | 7 |
higher incidence | 7 |
perioperative fluid | 7 |
traditional medicine | 7 |
data concerning | 7 |
traditional tidal | 7 |
hydroxyethyl starch | 7 |
retract system | 7 |
hospital outbreak | 7 |
airway pressures | 7 |
attending physicians | 7 |
pediatric trauma | 7 |
influenza pandemic | 7 |
excluded patients | 7 |
ventilator circuit | 7 |
related complications | 7 |
first time | 7 |
phase ii | 7 |
kg day | 7 |
ards according | 7 |
intravascular coagulation | 7 |
gas flow | 7 |
results obtained | 7 |
died within | 7 |
percutaneous coronary | 7 |
neurological recovery | 7 |
inlet cannula | 7 |
mpaw level | 7 |
sniffing position | 7 |
mottling score | 7 |
icu acquired | 7 |
first three | 7 |
lv diastolic | 7 |
french university | 7 |
henri mondor | 7 |
longer icu | 7 |
early detection | 7 |
standard criteria | 7 |
care society | 7 |
retrospectively reviewed | 7 |
statistical power | 7 |
tavem study | 7 |
factors influencing | 7 |
tissue infections | 7 |
acutely injured | 7 |
psychological consult | 7 |
cov outbreak | 7 |
diabetic patients | 7 |
severe pediatric | 7 |
developed ards | 7 |
refractory shock | 7 |
control ventilation | 7 |
spontaneous ventilation | 7 |
median icu | 7 |
cardiac arrests | 7 |
hemodynamic failure | 7 |
minimal inhibitory | 7 |
respiratory frequency | 7 |
hematopoietic stem | 7 |
lung edema | 7 |
care group | 7 |
tracheal secretions | 7 |
may provide | 7 |
overdistended regions | 7 |
macrophage recruitment | 7 |
prospective single | 7 |
dynamic compliance | 7 |
baumannii vap | 7 |
performed according | 7 |
blood lactate | 7 |
diabetes mellitus | 7 |
randomly assigned | 7 |
segment elevation | 7 |
syndrome acute | 7 |
invasive procedures | 7 |
also found | 7 |
receive either | 7 |
miserable outcome | 7 |
two hospitals | 7 |
practice guideline | 7 |
inspiratory support | 7 |
acinetobacter spp | 7 |
ecmo duration | 7 |
positive blood | 7 |
invasively ventilated | 7 |
increased morbidity | 7 |
past medical | 7 |
neurologic outcome | 7 |
oxygenation strategy | 7 |
dynamic strain | 7 |
weaning induced | 7 |
wide association | 7 |
required icu | 7 |
microbiological sampling | 7 |
different levels | 7 |
initial dose | 7 |
study demonstrates | 7 |
also performed | 7 |
among icu | 7 |
critical patients | 7 |
ethical committee | 7 |
arterial partial | 7 |
negative pressure | 7 |
attributable mortality | 7 |
physiological dead | 7 |
severely ill | 7 |
ngt placement | 7 |
placebo group | 7 |
multicenter retrospective | 7 |
attending physician | 7 |
acute cdi | 7 |
rsv patients | 7 |
french icu | 7 |
successful weaning | 7 |
icu physicians | 7 |
comatose patients | 7 |
syncytial virus | 7 |
secondary analysis | 7 |
received ecmo | 7 |
mainly related | 7 |
frequently used | 7 |
peep setting | 7 |
infections due | 7 |
first line | 7 |
co production | 7 |
xa activity | 7 |
clinical variables | 7 |
guidelines recommend | 7 |
airway opening | 7 |
producing gnb | 7 |
still alive | 7 |
tracheal aspirates | 7 |
flow index | 7 |
rv systolic | 7 |
icu ventilators | 7 |
describe organ | 7 |
viscoelastic behavior | 7 |
ecls implantation | 7 |
may allow | 7 |
vasopressor infusion | 7 |
invasive pulmonary | 7 |
pao mmhg | 7 |
team approach | 7 |
term prognosis | 7 |
algeria correspondence | 7 |
supplementary material | 7 |
lung fibrosis | 7 |
critical covid | 7 |
preliminary study | 7 |
adverse effect | 7 |
retrospective single | 7 |
acute asthma | 7 |
subgroup analysis | 7 |
severe disease | 7 |
hour urine | 7 |
acute pe | 7 |
hmpv infection | 7 |
first hour | 7 |
potential therapeutic | 7 |
cardiac failure | 7 |
also recorded | 7 |
pressure ventilation | 7 |
observational prospective | 7 |
microcirculatory dysfunction | 7 |
emergency departments | 7 |
mean length | 7 |
multivariate cox | 7 |
insertion site | 7 |
patients enrolled | 7 |
clinical findings | 7 |
receiving nmba | 7 |
resistance profile | 7 |
neurological disorders | 7 |
total bilirubin | 7 |
already discharged | 7 |
bacterial ecology | 7 |
dsi ne | 7 |
stenotrophomonas maltophilia | 7 |
venous return | 7 |
unit patients | 7 |
developing countries | 7 |
comorbid medical | 7 |
retrospective review | 7 |
gnb infection | 7 |
umbilical vein | 7 |
diaphragm thickness | 7 |
peep start | 7 |
induced ards | 7 |
per point | 7 |
sapsii score | 7 |
met criteria | 7 |
gas infection | 7 |
patients supported | 7 |
patients according | 7 |
median interquartile | 7 |
previous reports | 7 |
extracorporeal carbon | 7 |
lung biopsy | 7 |
serum concentrations | 7 |
less severe | 7 |
oxygen mask | 7 |
main etiologies | 7 |
immune function | 7 |
care protocol | 7 |
clinical suspicion | 7 |
bacterial clearance | 7 |
spontaneous circulation | 7 |
transient aki | 7 |
multivariable analysis | 7 |
palliative care | 7 |
kg predicted | 7 |
platelet counts | 7 |
severe complication | 7 |
iu ml | 7 |
orotracheal intubation | 7 |
several factors | 7 |
whole group | 7 |
three different | 7 |
care syndrome | 7 |
cytokine release | 7 |
cerebrospinal fluid | 7 |
sedative drugs | 7 |
clavulanic acid | 7 |
care setting | 7 |
pneumonia caused | 7 |
conventional methods | 7 |
recently published | 7 |
capillary leak | 7 |
shock populations | 7 |
control measures | 7 |
clinical situations | 7 |
higher icu | 6 |
medical surgical | 6 |
strongly related | 6 |
lung safe | 6 |
exhaled co | 6 |
steroid therapy | 6 |
ventilated children | 6 |
inferior vena | 6 |
experienced hfnc | 6 |
disseminated intravascular | 6 |
cardiac injury | 6 |
new technique | 6 |
postoperative complications | 6 |
maternal mortality | 6 |
target attainment | 6 |
studies suggest | 6 |
different methods | 6 |
lille university | 6 |
resistant staphylococcus | 6 |
metapneumovirus infection | 6 |
strongly correlated | 6 |
two different | 6 |
resistance index | 6 |
different time | 6 |
polymicrobial sepsis | 6 |
multicenter randomized | 6 |
larger cohort | 6 |
va ecmo | 6 |
dzp bup | 6 |
positron emission | 6 |
biomechanical analysis | 6 |
respiratory variables | 6 |
serum vancomycin | 6 |
plasma levels | 6 |
consensus conference | 6 |
experimental study | 6 |
adverse event | 6 |
isotonic saline | 6 |
paediatric intensive | 6 |
patients carrying | 6 |
adaptive ventilation | 6 |
electronic medical | 6 |
infection due | 6 |
viral loads | 6 |
specific population | 6 |
recipients admitted | 6 |
confirmed mers | 6 |
controlled adaptive | 6 |
severity index | 6 |
cci patients | 6 |
life threatening | 6 |
ancillary study | 6 |
dead patients | 6 |
light sedation | 6 |
sessions performed | 6 |
drug resistant | 6 |
cpis values | 6 |
sixteen patients | 6 |
icu admissions | 6 |
lower rate | 6 |
trial registration | 6 |
per log | 6 |
caring relationship | 6 |
min group | 6 |
cell disease | 6 |
gastric content | 6 |
severe hypoxia | 6 |
ritonavir group | 6 |
performance category | 6 |
abdominal sepsis | 6 |
analysis identified | 6 |
factor associated | 6 |
lymphopenic patients | 6 |
bacterial culture | 6 |
mean sofa | 6 |
moderate hypokalemia | 6 |
systolic pressure | 6 |
saps score | 6 |
may reduce | 6 |
local sign | 6 |
chinese traditional | 6 |
day one | 6 |
results highlight | 6 |
china clinical | 6 |
children treated | 6 |
muscular pressure | 6 |
baseline creatinine | 6 |
total number | 6 |
associated acute | 6 |
refeeding hypophosphoremia | 6 |
severity factors | 6 |
effective treatment | 6 |
evlw changes | 6 |
systolic excursion | 6 |
plasma concentration | 6 |
vt ml | 6 |
full access | 6 |
oral nutrition | 6 |
participating centers | 6 |
ethics approval | 6 |
convulsive status | 6 |
may affect | 6 |
day survivors | 6 |
liver dysfunction | 6 |
term outcome | 6 |
urine samples | 6 |
different clinical | 6 |
predictive values | 6 |
secondary outcome | 6 |
diseases society | 6 |
ddd dh | 6 |
alveolar collapse | 6 |
cumulative fluid | 6 |
early mortality | 6 |
ventilated icu | 6 |
i error | 6 |
study also | 6 |
serum pct | 6 |
severe ae | 6 |
respiratory diseases | 6 |
alveolitis profile | 6 |
unidentified etiology | 6 |
patients complicated | 6 |
parenchymal tethering | 6 |
major risk | 6 |
cause mortality | 6 |
unit mortality | 6 |
traumatic intracranial | 6 |
white blood | 6 |
ejection fraction | 6 |
ventilation settings | 6 |
strong agreement | 6 |
epinephrine group | 6 |
threatening organ | 6 |
positive pressure | 6 |
days iqr | 6 |
another study | 6 |
years period | 6 |
abdominal hypertension | 6 |
preliminary data | 6 |
ventilated critically | 6 |
better understand | 6 |
resistant pathogens | 6 |
creatine kinase | 6 |
tracheal aspirate | 6 |
care hospital | 6 |
ic patients | 6 |
acquired peritonitis | 6 |
evaluation ii | 6 |
low vt | 6 |
study patients | 6 |
standard therapy | 6 |
among non | 6 |
significant morbidity | 6 |
ventilatory parameters | 6 |
sepsis patients | 6 |
lung lesions | 6 |
arterial oxygenation | 6 |
hospital refractory | 6 |
research committee | 6 |
renal clearance | 6 |
immunosuppressive drugs | 6 |
female predominance | 6 |
limb ischemia | 6 |
year old | 6 |
changes induced | 6 |
creatinine level | 6 |
studies showed | 6 |
upper airway | 6 |
intravenous infusion | 6 |
infusion rate | 6 |
also showed | 6 |
influenza group | 6 |
cardiopulmonary bypass | 6 |
specialized journals | 6 |
per group | 6 |
arrest patients | 6 |
regional anticoagulation | 6 |
mainly due | 6 |
may influence | 6 |
internal jugular | 6 |
machine learning | 6 |
septic cardiomyopathy | 6 |
severe trauma | 6 |
fit testing | 6 |
lung inflation | 6 |
mdr bacteria | 6 |
routine use | 6 |
many patients | 6 |
medical literature | 6 |
underlying diseases | 6 |
viral clearance | 6 |
intrinsic peep | 6 |
ionized calcemia | 6 |
pregnant women | 6 |
norepinephrine group | 6 |
consensus definitions | 6 |
group vs | 6 |
icu capacity | 6 |
arterial hypertension | 6 |
intercostal muscles | 6 |
occlusion pressure | 6 |
rate variability | 6 |
membrane thrombosis | 6 |
included children | 6 |
crs changes | 6 |
intravascular volume | 6 |
oxygen administration | 6 |
mv weaning | 6 |
mean value | 6 |
sedated patients | 6 |
main cause | 6 |
empirical treatment | 6 |
filter lifespan | 6 |
lower risk | 6 |
short term | 6 |
mean total | 6 |
confirmed covid | 6 |
pp session | 6 |
cmv group | 6 |
immune cells | 6 |
significant impact | 6 |
dependent regions | 6 |
mechanical breath | 6 |
base deficit | 6 |
chest pain | 6 |
analytical study | 6 |
two hundred | 6 |
critical cases | 6 |
safe study | 6 |
median iqr | 6 |
organ function | 6 |
ecmo center | 6 |
false positive | 6 |
total costs | 6 |
ebola virus | 6 |
outcome measure | 6 |
derecruited volume | 6 |
international consensus | 6 |
daily clinical | 6 |
hospital staff | 6 |
sectional study | 6 |
dap values | 6 |
allowed us | 6 |
major public | 6 |
mean airway | 6 |
received mechanical | 6 |
endothelial glycocalyx | 6 |
dysfunction syndrome | 6 |
predicting mortality | 6 |
definite probable | 6 |
trend toward | 6 |
care facilities | 6 |
support organization | 6 |
improve patient | 6 |
random effect | 6 |
mixed effect | 6 |
nucleic acid | 6 |
intravenous immunoglobulins | 6 |
frequent cause | 6 |
hemodynamic tolerance | 6 |
low level | 6 |
common reason | 6 |
cov patients | 6 |
fluid cytology | 6 |
icu survival | 6 |
tissue hypoperfusion | 6 |
fatality rate | 6 |
saudi ministry | 6 |
normal distribution | 6 |
severe cap | 6 |
wall elastance | 6 |
ct images | 6 |
short time | 6 |
parasternal intercostal | 6 |
symptomatic treatment | 6 |
differ significantly | 6 |
gram negative | 6 |
interval ci | 6 |
antimicrobial stewardship | 6 |
well described | 6 |
pressure transducer | 6 |
decision making | 6 |
requiring intensive | 6 |
endothelial cell | 6 |
severe head | 6 |
fatal poisoning | 6 |
vessel density | 6 |
empiric antibiotic | 6 |
immune suppression | 6 |
lung homogeneity | 6 |
altitude pulmonary | 6 |
prevention program | 6 |
clinical breakpoints | 6 |
ei group | 6 |
opposition rate | 6 |
salbutamol nebulization | 6 |
findings suggest | 6 |
vital status | 6 |
oxygen partial | 6 |
protection des | 6 |
vulnerable patients | 6 |
negative fluid | 6 |
medical charts | 6 |
modified sofa | 6 |
standard method | 6 |
french hospitals | 6 |
gene expression | 6 |
global mortality | 6 |
patients characteristics | 6 |
medical resources | 6 |
cardiovascular events | 6 |
main characteristics | 6 |
cannula group | 6 |
respiratory status | 6 |
strain progression | 6 |
bed availability | 6 |
nasopharyngeal swabs | 6 |
recent years | 6 |
received enteral | 6 |
recumbent position | 6 |
worse outcome | 6 |
intubation procedure | 6 |
withdrawal syndrome | 6 |
non invasive | 6 |
affiliations none | 6 |
wide range | 6 |
ecmo implementation | 6 |
study date | 6 |
biological parameters | 6 |
cardiovascular dysfunction | 6 |
major bleeding | 6 |
associated factors | 6 |
remains unknown | 6 |
cox proportional | 6 |
last decade | 6 |
rbc transfusion | 6 |
pain assessment | 6 |
hospital ibn | 6 |
venous hemofiltration | 6 |
cd group | 6 |
inflammatory conditions | 6 |
venous catheterization | 6 |
small vessels | 6 |
cell transplant | 6 |
viral treatment | 6 |
trend towards | 6 |
th percentile | 6 |
conservative fluid | 6 |
improve arterial | 6 |
using univariate | 6 |
base equilibrium | 6 |
critical opening | 6 |
hr values | 6 |
validation study | 6 |
methods retrospective | 6 |
empirical antibiotic | 6 |
calculated just | 6 |
two independent | 6 |
larger studies | 6 |
ards severity | 6 |
based indices | 6 |
outcome scale | 6 |
syndrome secondary | 6 |
first draft | 6 |
high probability | 6 |
strong recommendation | 6 |
icu healthcare | 6 |
viral shedding | 6 |
pulmonary microvascular | 6 |
psychological disorders | 6 |
systolic pulmonary | 6 |
healthcare professionals | 6 |
exact tests | 6 |
strain maps | 6 |
epidemiological profile | 6 |
treated medically | 6 |
delivery room | 6 |
therapeutic interventions | 6 |
accelerate pheno | 6 |
peep titration | 6 |
acute ischemic | 6 |
diastolic pressure | 6 |
without mv | 6 |
fatal carbon | 6 |
mean risk | 6 |
requiring invasive | 6 |
results show | 6 |
epithelial cells | 6 |
respiratory assistance | 6 |
emission tomography | 6 |
statistical difference | 6 |
study clinical | 6 |
negative impact | 6 |
january st | 6 |
lung protection | 6 |
cell deficiency | 6 |
regional hospital | 6 |
vascular access | 6 |
study found | 6 |
tranexamic acid | 6 |
nssh patients | 6 |
may impact | 6 |
qualitative data | 6 |
microbiologically confirmed | 6 |
using clinical | 6 |
control patients | 6 |
line treatment | 6 |
glasgow outcome | 6 |
minor allele | 6 |
one icu | 6 |
results among | 6 |
vasopressor start | 6 |
early stages | 6 |
french society | 6 |
artery bypass | 6 |
thyroid storm | 6 |
adults admitted | 6 |
last decades | 6 |
ards group | 6 |
organ donor | 6 |
using different | 6 |
per cent | 6 |
measured fio | 6 |
radiological findings | 6 |
similar findings | 6 |
filter ionized | 6 |
better understanding | 6 |
may occur | 6 |
least two | 6 |
march th | 6 |
support levels | 6 |
surgical resuscitation | 6 |
weight loss | 6 |
using two | 6 |
medical center | 6 |
second part | 6 |
cerebral performance | 6 |
made using | 6 |
dendritic cells | 6 |
ineffective triggering | 6 |
lps animals | 6 |
significant improvement | 6 |
sars patients | 6 |
assistance publique | 6 |
observational retrospective | 5 |
endobronchial intubation | 5 |
renal dysfunction | 5 |
shock following | 5 |
management strategies | 5 |
patient care | 5 |
peep decrease | 5 |
microbiologically documented | 5 |
functional outcome | 5 |
initial lactate | 5 |
oran hospital | 5 |
initial treatment | 5 |
ecmo insertion | 5 |
proper use | 5 |
congestive heart | 5 |
severe illness | 5 |
clinical use | 5 |
lung volumes | 5 |
effects related | 5 |
recruitment pattern | 5 |
icu specialized | 5 |
remains challenging | 5 |
vasopressor dose | 5 |
serum concentration | 5 |
gas analysis | 5 |
lung compliance | 5 |
icu nurses | 5 |
absolute value | 5 |
perfused vessel | 5 |
nutric score | 5 |
common practice | 5 |
ventilatorassociated pneumonia | 5 |
patient comfort | 5 |
gastric tube | 5 |
isolated microorganisms | 5 |
antimicrobial treatment | 5 |
cerebral edema | 5 |
see table | 5 |
three days | 5 |
central line | 5 |
rnapol autoantibodies | 5 |
table shows | 5 |
experimental models | 5 |
female gender | 5 |
phase duration | 5 |
two main | 5 |
dilution method | 5 |
substantial contribution | 5 |
severely burned | 5 |
ards caused | 5 |
predict outcome | 5 |
hypoxic vasoconstriction | 5 |
pancreatic surgery | 5 |
likely due | 5 |
positive expiratory | 5 |
hospital setting | 5 |
central catheter | 5 |
diaphragm function | 5 |
iu kg | 5 |
ventilator days | 5 |
spectrum antibiotics | 5 |
new simplified | 5 |
study assessing | 5 |
may benefit | 5 |
artificial ventilation | 5 |
neurosurgical care | 5 |
cell death | 5 |
massive influx | 5 |
samples taken | 5 |
acquiring mers | 5 |
time curve | 5 |
including pneumonia | 5 |
cicu stay | 5 |
liquid chromatography | 5 |
invasive method | 5 |
jc sessions | 5 |
ventricular afterload | 5 |
hfnc oxygen | 5 |
ventilation parameters | 5 |
ino alone | 5 |
therapeutic decisions | 5 |
brief expiratory | 5 |
independent prognostic | 5 |
synthetase syndrome | 5 |
early administration | 5 |
syndrome date | 5 |
retrospectively included | 5 |
imv ae | 5 |
increased duration | 5 |
concern patients | 5 |
ventilation mode | 5 |
ards complicating | 5 |
also considered | 5 |
medical file | 5 |
nflp group | 5 |
death among | 5 |
hospital anxiety | 5 |
presenting symptoms | 5 |
current treatment | 5 |
adult icu | 5 |
hemorrhagic transformation | 5 |
sfm guidelines | 5 |
biological factors | 5 |
great interest | 5 |
emergency medicine | 5 |
autonomic nervous | 5 |
emotional support | 5 |
frozen plasma | 5 |
experimental studies | 5 |
groups using | 5 |
oxygen circuit | 5 |
clinical criteria | 5 |
also studied | 5 |
psychological support | 5 |
traumatic aki | 5 |
skin samples | 5 |
neck flexion | 5 |
drug users | 5 |
dead organ | 5 |
testosterone gel | 5 |
bl overdosing | 5 |
statistical software | 5 |
arterial extracorporeal | 5 |
multiorgan failure | 5 |
bypass graft | 5 |
burn care | 5 |
preload dependence | 5 |
strain heterogeneity | 5 |
also used | 5 |
france full | 5 |
lung pathology | 5 |
european north | 5 |
patients suffered | 5 |
autoimmune diseases | 5 |
children hospitalized | 5 |
third international | 5 |
many studies | 5 |
healthcare team | 5 |
non survivors | 5 |
piriform sinus | 5 |
therapeutic strategy | 5 |
assist may | 5 |
new treatments | 5 |
confounding variables | 5 |
induced immune | 5 |
first cause | 5 |
resistance rates | 5 |
dioxide gap | 5 |
insulin resistance | 5 |
th day | 5 |
remained independently | 5 |
oussama jaoued | 5 |
bed mixed | 5 |
depression scale | 5 |
cumulative dose | 5 |
human beings | 5 |
upper airways | 5 |
second period | 5 |
regional citrate | 5 |
sepsis admitted | 5 |
better outcome | 5 |
crossover study | 5 |
low molecular | 5 |
nutrition support | 5 |
specific treatment | 5 |
university teaching | 5 |
acute severity | 5 |
vv ecmo | 5 |
emergency resuscitation | 5 |
well tolerated | 5 |
thrombotic complications | 5 |
associated infections | 5 |
experimental data | 5 |
esbls producing | 5 |
theoretical immediate | 5 |
last follow | 5 |
attempt success | 5 |
patient admitted | 5 |
burnout syndrome | 5 |
immune dysfunction | 5 |
clinical relevance | 5 |
aki patients | 5 |
hemolytic anemia | 5 |
put forward | 5 |
therapeutic targets | 5 |
evaluate whether | 5 |
inflammatory markers | 5 |
french guidelines | 5 |
hospital workers | 5 |
difference regarding | 5 |
elevated pulmonary | 5 |
medical ethics | 5 |
eighteen patients | 5 |
acquired infection | 5 |
experimental ards | 5 |
pressure cmh | 5 |
patients alive | 5 |
predict poor | 5 |
frequently identified | 5 |
ventricular systolic | 5 |
clinical evaluation | 5 |
nosocomial enterococcus | 5 |
two university | 5 |
sustaining therapy | 5 |
corporeal membrane | 5 |
nmo attacks | 5 |
intracranial hemorrhage | 5 |
four groups | 5 |
contralateral rotation | 5 |
ventricular function | 5 |
oxygen titration | 5 |
lung stress | 5 |
cerebral insults | 5 |
hypnosis sessions | 5 |
randomly allocated | 5 |
trough concentration | 5 |
traumatic cause | 5 |
tertiary referral | 5 |
showed significant | 5 |
bal samples | 5 |
median number | 5 |
prognostic marker | 5 |
calcium channel | 5 |
arf revealing | 5 |
taken together | 5 |
common complication | 5 |
high blood | 5 |
multicentre study | 5 |
malignancies admitted | 5 |
aged less | 5 |
ss patients | 5 |
time reverse | 5 |
frequent among | 5 |
inflammatory state | 5 |
breakpoints according | 5 |
myocardial involvement | 5 |
important part | 5 |
severe dyspnea | 5 |
progressively higher | 5 |
complement activation | 5 |
weaning success | 5 |
aerosol delivery | 5 |
cpc score | 5 |
kg per | 5 |
sensitivity analysis | 5 |
five cases | 5 |
venous thrombosis | 5 |
require mechanical | 5 |
plasma protein | 5 |
worse sofa | 5 |
mental status | 5 |
general electric | 5 |
community peritonitis | 5 |
high volume | 5 |
also similar | 5 |
peep increases | 5 |
also demonstrated | 5 |
dialysis sessions | 5 |
scls attacks | 5 |
mechanisms involved | 5 |
corrected age | 5 |
liver disease | 5 |
therapeutic limitation | 5 |
sickle cell | 5 |
massive transfusion | 5 |
including ventilator | 5 |
viral copathogen | 5 |
ventilated lung | 5 |
mechanical properties | 5 |
mean apache | 5 |
published data | 5 |
hyperammonemic encephalopathy | 5 |
probably due | 5 |
strong ion | 5 |
anoxic comatose | 5 |
hemorrhagic complications | 5 |
sepsis diagnosis | 5 |
medical systems | 5 |
initial antibiotic | 5 |
underwent mechanical | 5 |
nephrotoxic drugs | 5 |
spectrum antiviral | 5 |
modified rankin | 5 |
north american | 5 |
venous access | 5 |
severe organ | 5 |
visual analogic | 5 |
multivariate model | 5 |
target range | 5 |
artery pressure | 5 |
catheter related | 5 |
appropriate antimicrobial | 5 |
fluid removal | 5 |
study groups | 5 |
ten cases | 5 |
submitted work | 5 |
plasma concentrations | 5 |
young children | 5 |
one study | 5 |
treatment initiation | 5 |
study spread | 5 |